Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects.

Ascites Clinical Trial

Official title:

Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04641364
• Other study ID #: ART-2019-001
• Status: Completed
• Phase: Phase 1
• Start date: June 24, 2019
• Est. completion date: May 6, 2020

Study information

• Verified date: September 2020
• Source: First Hospital of Jilin University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A phase I, single-center, randomized, double-blind, placebo-controlled single dose escalation study, and a positive-controlled multiple dose extension study to evaluate the safety, tolerance, pharmacokinetics and immunogenicity of recombinant human albumin injection in healthy subjects

Description:

This study was to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of recombinant human albumin injection in healthy volunteers. The safety, tolerance, pharmacokinetics and immunogenicity of recombinant human albumin injection were evaluated in a single center, randomized, double-blind, placebo-controlled single dose incremental trial in healthy volunteers. The study was divided into two stages: the first stage was a single dose and dose increasing stage (including 5 dose groups with increasing dose, and each group was set with placebo control); the second stage was multiple administration stage (with positive control). The safety, tolerance, pharmacokinetics, immunogenicity and other early clinical data of recombinant human albumin were collected and analyzed in the two stages. The initial dose was 1.25g. The highest dose group was set at 30g. The dose groups of 1.25, 5, 10, 20 and 30 g / time were preset in the single dose stage (dose increasing stage). The dosage was 10 g / Day in multiple administration stage.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: May 6, 2020
• Est. primary completion date: May 6, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1)Informed consent form signed; 2) To be able to complete the study; 3) Subjects (including partners) are willing to take contraceptive measures; 4) 18-55 years of age; 5) Male subjects are no less than 50 kg.Female subjects are no less than 45 kg. Body mass index is 18-28kg / m2; 6) Normal cardiac function, defined as left ventricular ejection fraction (LVEF) = 50%; 7) Physical examination and vital signs are normal.

Exclusion Criteria:

1. Cigarettes Smoking subjects.

2. Allergic constitution (multiple drugs and food allergies);

3. History of drug use and/or alcohol abuse;

4. Blood donation or massive blood loss (> 450 mL) within three months before screening;

5. Taking any drugs, prescription, over-the-counter, vitamin products or herbal medicine within 14 days before screening;

6. Diet or exercise have changed recently;

7. Using study drugs within three months;

8. Risk of bleeding, such as hemorrhoids, acute gastritis or stomach and duodenal ulcers;

9. ECG abnormalities (QTc > 470ms for males, > 480ms for females);

10. Female subjects are in lactation. Pregnancy test is positive;

11. Other Clinical laboratory tests abnormalities;

12. Viral screening test is positive, including HBV, HCV, HIV, and Treponema pallidum;

13. Developing Acute disease;

14. Eating chocolate, any caffeine-containing or jaundice-rich food or drink 24 hours prior to the use of the study drug;

15. Taking any alcoholic products. Alcohol test is positive..

16. Drug test is positive. History of drug abuse or drug use in the past five years;

17. Inability for intravenous injection or blood collection;

18. Using biological products (including live vaccines) within the last 3 months. Planing to use vaccines during the study period. Having received corticosteroid or human plasma product system treatment within 1 month.

19. Renal function is abnormal, glomerular filtration rate <80 mL/min (according to the simplified MDRD formula);

20. History of glaucoma, eye disease.

21. History of cancer or other serious systemic diseases, especially heart, liver, kidney, digestive tract, nervous system, metabolic abnormalities, immune abnormalities or mental disorders;

22. History of immunodeficiency or hypofunction;

23. Received major surgery within 2 years.

24. Other subjects by investigator opinion..

Related Conditions & MeSH terms

• Ascites

Intervention

Drug:
• recombinant human albumin injection
single dose or multiple doses of intravenous infusion
• Placebo
Single dose intravenous infusion of 0.9% sodium chloride injection
• human albumin injection
multiple doses of intravenous infusion

Locations

Country	Name	City	State
China	the first hospital of Jilin University	Changchun	Jilin

Sponsors (1)

Lead Sponsor	Collaborator
First Hospital of Jilin University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerance	AE	Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study.
Secondary	PK parameters	Maximum Plasma Concentration(Cmax)	Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study.
Secondary	PK parameters	time to Maximum Plasma Concentration(Tmax)	Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study.
Secondary	PK parameters	half life (t1/2)	Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study.
Secondary	Pharmacodynamic parameters	Red blood cell specific volume	Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study.
Secondary	Pharmacodynamic parameters	Plasma colloid osmotic pressure	Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study.
Secondary	Immunogenicity	Percentage of patients with positive reaction	Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study.